About Drugzsphere
We're the desk overseas buyers actually wanted.
Our story
A family pharma backbone, sharpened for export.
India supplies roughly one in every five generic doses on the planet. Yet the experience of buying from India — for an importer in Lagos, Manila or Lima — is often messy: scattered contacts, inconsistent dossiers, vague quality claims and slow responses.
Drugzsphere was set up to fix that gap, working alongside a network of WHO-GMP, EU-GMP and USFDA-aligned manufacturers — many built on decades of family-run pharma manufacturing roots — and translating that capacity into a single, accountable point of contact for international buyers.
We're not the largest exporter in India. We're built to be the most reliable one for the markets we serve — and to behave like a long-term sourcing partner, not a transactional trader.
What makes us different
Four things our buyers tell us they pay us for.
A single accountable contact
One person owns your account — across products, plants, documents and shipments. You stop chasing five email threads to close one order.
Regulatory affairs as a service
We don’t hand you a product and say "good luck registering it." Dossier preparation (CTD/ACTD), DMF support, artwork in local language and post-registration changes are part of the deal.
Vetted manufacturer network
We only source from WHO-GMP certified facilities, ideally with EU-GMP or USFDA approvals. We share plant names, scope of approvals and country of registration — not generic "ISO-certified" claims.
ROW-first thinking
Pricing, MOQs, packaging and language are designed around how Africa, LATAM, MENA, CIS and SE Asia actually procure pharma — not retrofitted from a US/EU model.
How we operate
Three operating non-negotiables.
Document-complete
No shipment leaves without the documents your local authority needs — verified before dispatch.
Response within 24 hours
Every inquiry gets a structured answer within one business day. No black holes, no follow-up tax.
Transparency by default
Plant names, approvals and dossier status are shared openly under NDA — no smoke, no proxy claims.